Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Solid Tumour - Overview - Disease Synopsis

Drugs & Clinical Candidates


5 drugs have received FDA approval for Solid Tumour . Dactinomycin, Denosumab, LAROTRECTINIB SULFATE, Pembrolizumab and Rasburicase
0 drugs have a clinical trial registered for Solid Tumour.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 0 clinical trials for Solid Tumour,
0 of which have one or more drug interventions,
0 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 0 Cell Line Models for Solid Tumour.

Source: COSMIC
(see details)

Chemistry


There are 5954 Compounds which have been tested in Solid Tumour , 3889 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Solid Tumour:


The following terms have been mapped from cancer.gov to Solid Tumour:
Broken bones and other bone problems caused by multiple myeloma or by solid tumors that have metastasized (spread) to bone. This use is approved for the Xgeva brand of denosumab
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that is metastatic and cannot be removed by surgery. It is used in adults and children for:Solid tumors that have gotten worse after other treatment or that cannot be treated with other therapies.????
Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in tropomyosin receptor kinase (TRK) protein. It is used in adults and children whose cancer has metastasized (spread to other parts of the body) or cannot be removed by surgery and cannot be treated with other therapies or has gotten worse after other treatment
Solid tumors. It is used as palliative and/or adjuvant therapy for disease that has recurred (come back)
Tumor lysis syndrome in patients with leukemia, lymphoma, or malignant solid tumors. It is used when the treatment is expected to cause high blood levels of uric acid